Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 4, 2013, Pages

  Angelico, Francesco ^a   Alessandri, Cesare ^a   Del Ben, Maria ^a   Lirussi, Flavio ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b WHO European Office for Investment for Health and Development   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PRIORITY JOURNAL; RETRACTED ARTICLE; REVIEW;

EID: 85041823681     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD005166.pub3     Document Type: Review

References (65)

1. Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N, et al.A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Americal Journal of Gastroenterology 2005;100(5):1082-90.
2. Sanyal AJ, Mofrad PS, Contos MJ, Sargeant C, Luketic VA, Sterling RK, et al.A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clinical Gastroenterology and Hepatology 2004;2:1107-15.
3. Uygun A, Kadayifci A, Isik AT, Ozgurtas T, Deveci S, Tuzun A, et al.Metformin in the treatment of patients with non-alcoholic steatohepatitis. Alimentary Pharmacology & Therapeutics 2004;19(5):537-44. [MEDLINE: 14987322].
4. Abdelmalek MF, Angulo P, Jorgensen RA, Sylvestre PB, Lindor KD. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. American Journal of Gastroenterology 2001;96(9):2711-7. [MEDLINE: 11569700].
5. Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC, Battle EH, Sheppard BL. A pilot study of thiazolidinedione, troglitazone in nonalcoholic steatohepatitis. American Journal of Gastroenterology 2001;96(2):519-25. [MEDLINE: 11232700].
6. De Fronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28(5):1092-100.
7. Duseja A, Murlidharan R, Bhansali A, Sharma S, Das A, Das R, et al.Assessment of insulin resistance and effect of metformin in nonalcoholic steatohepatitis - a preliminary report. Indian Journal of Gastroenterology 2004;23(1):12-5. [MEDLINE: 15106708].
8. Itoh S, Kanazuka A, Akimoto T. Combined treatment with ursodeoxycholic acid and pioglitazone in a patient with type 2 diabetes and psoriasis. Digestive Diseases and Sciences 2003;48(11):2182-6. [MEDLINE: 14705825].
9. Katoh S, Hata S, Matsushima M, Ikemoto S, Inoue Y, Yokoyama J, et al.Troglitazone prevents the rise in visceral adiposity and improves fatty liver associated with sulfonylurea therapy. A randomized controlled trial. Metabolism 2001;50(4):414-7. [MEDLINE: 11288035].
10. Lebovitz HE, Kreider M, Freed MI. Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care 2002;25(5):815-21. [MEDLINE: 11978674].
11. Lindor KD, Kowdley KV, Heathcote EJ, Harrison ME, Jorgensen R, Angulo P, et al.Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004;39(3):770-8. [MEDLINE: 14999696].
12. Lirussi F, Beccarello A, Zanette G, De Monte A, Donadon V, Velussi M, et al.Silybin-beta-cyclodextrin in the treatment of patients with diabetes mellitus and alcoholic liver disease. Efficacy study of a new preparation of an anti-oxidant agent. Diabetes, Nutrition Metabolism 2002;15(4):222-31.
13. Magalotti D, Marchesini G, Ramilli S, Berzigotti A, Bianchi G, Zoli M. Splanchnic haemodynamics in non-alcoholic fatty liver disease: effect of a dietary/pharmacological treatment. A pilot study. Digestive and Liver Disease 2004;36(6):406-11.
14. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet 2001;358(9285):893-4. [MEDLINE: 11567710].
15. Menon KVN, Angulo P, Lindor KD. Severe cholestatic hepatitis from troglitazone in a patient with nonalcoholic steatohepatitis and diabetes mellitus. American Journal of Gastroenterology 2001;96(5):1631-4. [MEDLINE: 11374713].
16. Nair S, Diehl AM, Wiseman M, Farr GH Jr, Perrillo RP. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Alimentary Pharmacology & Therapeutics 2004;20(1):23-8.
17. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with PPAR-gamma ligand rosiglitazone. Hepatology 2003;38(4):1008-17. [MEDLINE: 14512888].
18. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Sponseller CA, Hampton K, Bacon BR. Interim results of a study demonstrating the early effects of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis. Journal of Hepatology 2003;38(4):434-40. [MEDLINE: 12663234].
19. Nohara S, Iwase M, Nakamura U, Azuma K, Iwai K, Iida M. A case of obese type 2 diabetes mellitus associated with nonalcoholic steatohepatitis (NASH) treated with a combined therapy of glimepiride and insulin. Journal of the Japan Diabetes Society 2003;46(11):873-9. [2004009830].
20. Ott P, Ranek L, Young MA. Pharmacokinetics of troglitazone, a PPAR-gamma agonist, in patients with hepatic insufficiency. European Journal of Clinical Pharmacology 1998;54(7):567-71.
21. Promrat K, Lutchman G, Uwaifo GI, Freedman RJ, Soza A, Heller T, et al.A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004;39(1):188-96. [MEDLINE: 14752837].
22. Schwimmer JB, Middleton MS, Deutch R, Lavine JE. A phase 2 clinical trial of metformin as a treatment for non-diabetic paedriatic non-alcoholic steatohepatitis. Alimentary Pharmacology & Therapeutics 2005;21(7):871-9.
23. Shadid S, Jensen MD. Effect of piglitazone on biochemical indices of non-alcoholic fatty liver disease in upper body obesity. Clinical Gastroenterology and Hepatology 2003;1(5):384-7. [MEDLINE: 15017657].
24. Shadid S, Jensen MD. Effects of pioglitazone versus diet and exercise on metabolic health and fat distribution in upper body obesity. Diabetes Care 2003;26(11):3148-52.
25. Sulkin TV, Bosman D, Krentz AJ. Contraindications to metformin therapy in patients with NIDDM. Diabetes Care 1997;20(6):925-8.
26. Urso R, Visco-Comandini U. Metformin in non-alcoholic steatohepatitis. Lancet 2002;359(9303):355-6. [MEDLINE: 11830232].
27. Gensthaler BM. Metformin therapy for fatty liver. Pharmazeutische Zeitung 2000;145(35):26.
28. Leiss O, Linhart P. Treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Verdauungskrankheiten 2003;21(2):94-100. [2003260602].
29. Angelico F, Del Ben M, Conti R, Francioso F, Feole K, Maccioni D, et al.Non-alcoholic fatty liver syndrome: a hepatic consequence of common metabolic diseases. Journal of Gastroenterology and Hepatology 2003;18(5):588-94.
30. Angelico F, Del Ben M, Conti R, Francioso S, Feole K, Fiorello S, et al.Insulin resistance, the metabolic syndrome and nonalcoholic fatty liver disease. Journal of Clinical Endocrinology and Metabolism 2005;90(3):1578-82.
31. Angulo P. Nonalcoholic fatty liver disease. New England Journal of Medicine 2002;16:1221-31.
32. Angulo P, Lindor KD. Treatment of non-alcoholic steatohepatitis. Best Practice & Research Clinical Gastroenterology 2002;16(5):797-810.
33. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Non-alcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994;107(4):1103-9.
34. Becker U, Deis A, Sorensen TI, Gronbæk M, Borch-Johnsen K, Florvall Muller C, et al.Prediction of risk of liver disease by alcohol intake, sex and age: a prospective population study. Hepatology 1996;23(5):1025-9.
35. Brolin RE, Bradley LJ, Taliwal RV. Unsuspected cirrhosis discovered during elective obesity operations. Archives of Surgery 1998;133(1):84-8.
36. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. American Journal of Gastroenterology 1999;94(9):2467-74.
37. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, et al.Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002;123(1):134-40.
38. Calwell SH, Oelsner DH, Iezzoni J, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999;29(3):664-9.
39. Chitturi S, Farrell GC. Etiopathogenesis of non-alcoholic steatohepatitis. Seminars in Liver Disease 2001;21(1):27-41.
40. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, et al.NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002;35(2):373-9.
41. Day CP, James OF. Steatohepatitis: a tale of two "hits"?. Gastroenterology 1998;114(4):842-5.
42. DeMets DL. Methods for combining randomized clinical trials: strengths and limitations. Statistics in Medicine 1987;6(3):341-50.
43. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177-88.
44. Dixon JB, Bhathal PS, Hughes NR, O'Brien PE. Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology 2004;39(6):1647-54.
45. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical Research Ed.) 1997;315(7109):629-34.
46. Farrell GC. Non-alcoholic steatohepatitis: what is it, and why is it important in the Asia-Pacific region?. Journal of Gastroenterology and Hepatology 2003;18(3):124-38.
47. Gluud C. Alcoholic hepatitis: no glucocorticosteroids?. In: Leuschner U, James OFW, Dancygier H editor(s). Steatohepatitis (NASH and ASH), Falk Symposium 121. Dordrecht, NL: kluwer Academic Publishers, 2001:322-42.
48. Gluud C, Als-Nielsen B, D'Amico G, Fingerhut A, Gluud LL, Khan S, et al.Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2006, Issue 3. Art. No.: LIVER.
49. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]. The Cochrane Library, Issue 4, 2006. Chichester, UK: John Wiley & sons, Ltd.
50. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine 2001;135(11):982-9.
51. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al.Formulation and application of a numerical score system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1(5):431-5.
52. Lavine JE, Schwimmer JB. Nonalcoholic fatty liver disease in the pediatric population. Clinics in Liver Disease 2004;8(3):549-58, viii-ix.
53. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, et al.Association of nonalcoholic fatty liver disease with insulin resistance. American Journal of Medicine 1999;107(5):450-5.
54. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, et al.Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50;8:1844-50.
55. McCullough AJ. Update on nonalcoholic fatty liver disease. Journal of Clinical Investigation 2002;34(3):255-62.
56. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al.Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352(9128):609-13.
57. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003;37(5):1202-19.
58. Poonawala A, Nair S, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology 2000;32:689-92.
59. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 4.2 for Windows. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2003.
60. Royle P, Milne R. Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care 2003;19(4):591-603.
61. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, et al.Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001;120(5):1183-92.
62. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-12.
63. Te Sligte K, Bourass I, Sels JP, Driessen A, Stockbrugger RW, Koek GH. Non-alcoholic steatohepatitis: review of a growing medical problem. European Journal of Internal Medicine 2004;15(1):10-21.
64. Wang RT, Koretz RL, Yee HF. Weight reduction for non-alcoholic fatty liver. (Protocol) The Cochrane Database of Systematic Reviews 2002, Issue 1. Art. No.: CD003619. DOI: 10.1002/14651858.CD003619. Chichester, UK: John Wiley & Sons, Ltd.
65. Younossi ZM, Diehl AM, Ong JP. Nonalcoholic fatty liver disease: an agenda for clinical research. Hepatology 2002;34(4):450-5.